How is depression in adolescents different from normal teenage moodiness?

Normal adolescent development involves moodiness, identity exploration, and heightened emotion — this is expected and does not meet criteria for depression. Pathological depression requires at least five DSM-5 symptoms (including depressed or irritable mood, or loss of interest) persisting most of the day, most days, for at least two weeks, with real impairment in school, social, or home functioning. Irritability — not just sadness — is a common dominant feature in adolescents with depression. Other clues: withdrawal from friends and activities, school refusal, significant changes in sleep or appetite, and expressions of hopelessness or worthlessness that are disproportionate to circumstances.

Is it safe to use antidepressants in young people?

Antidepressants — including fluoxetine — are used for moderate to severe adolescent depression when therapy alone is insufficient. The TGA (and FDA) require a Black Box Warning for all antidepressants in under-25-year-olds: there is a small increase (about 1–2%) in suicidal thoughts and behaviours in the first 2–4 weeks of treatment. Weekly review during this period is required. Crucially, untreated moderate-to-severe depression carries a higher overall suicide risk than treated depression — the benefit-risk analysis still supports treatment when indicated. The decision is made carefully, with fully informed consent from the young person and their family.

What is headspace and how does my young person get there?

headspace is Australia's national youth mental health organisation, operating 115+ centres that provide multidisciplinary mental health care for people aged 12–25. Services include GPs, psychologists, social workers, and alcohol and other drug workers. Many services are bulk-billed or low-cost. A GP referral is helpful but not required for an initial headspace appointment. Walk-in is accepted at many centres. eheadspace (1800 650 890) provides telehealth support for those who cannot access a local centre, including rural and remote young people. headspace is the most accessible entry point for mild-to-moderate youth mental health concerns across Australia.

What should I do if a young person mentions thoughts of suicide?

Ask directly and calmly — research confirms that asking about suicide does not increase risk. Assess the level of risk: has the young person thought about how they might do it, made any preparations, or made a previous attempt? A safety plan — ideally co-produced using the Stanley-Brown approach — identifies warning signs, coping strategies, people to contact, and reasons for living. Ensure means restriction: medications should be stored locked, firearms removed, and paracetamol limited in the household. Active suicidal plan with intent and access to means requires same-day emergency assessment. The Beyond Now app (beyondblue) supports digital safety planning.

What therapy works best for adolescent depression?

Cognitive behavioural therapy (CBT) and interpersonal therapy for adolescents (IPT-A) are both first-line psychological treatments for moderate adolescent depression with strong evidence. For severe depression, the TADS trial (published in NEJM 2007) showed that combining CBT with fluoxetine produced a 71% response rate — significantly better than either treatment alone. In Australia, therapy is accessed via a Mental Health Care Plan and referral to a psychologist through the Better Access program (up to 10 sessions per year) or through headspace centres, which often have integrated psychological services.

Adolescent major depressive disorder

Adolescent depression: AU general practice assessment and treatment

By Dr HB Lo, FACRRM Reviewed 1 July 2026 10 min read

Depression affects roughly 13% of Australian adolescents and is the second leading cause of death in 15–24-year-olds.

Treatment is stepped by severity: lifestyle and psychoeducation for mild; CBT or IPT-A for moderate; combined CBT and fluoxetine for severe. Fluoxetine is the only TGA-approved SSRI for adolescent depression. All antidepressants in under-25-year-olds carry a TGA Black Box Warning — weekly review for the first four weeks is required.

headspace (115+ centres, ages 12–25) is the main referral pathway. Complex presentations go to Child and Youth Mental Health Services (CYMHS).

What adolescent depression actually is

Adolescent depression — encompassing Major Depressive Disorder, Persistent Depressive Disorder, and adjustment disorder with depressed mood in people aged roughly 12–25 — is not the same as normal teenage moodiness. The clinical task is distinguishing developmentally expected phenomena (transient emotional volatility, identity exploration, peer focus, sleep-phase delay) from pathological depression that meets criteria and causes impairment.

DSM-5 MDD criteria require ≥5 symptoms for ≥2 weeks, including at least one of depressed mood or anhedonia (loss of interest), plus accompanying symptoms — sleep or appetite change, fatigue, psychomotor change, poor concentration, worthlessness or excessive guilt, recurrent thoughts of death. Crucially, irritability counts as a mood symptom in adolescents, not just sadness. Functional impairment in school, family, or social domains is required to meet threshold.

Per AIHW, approximately 13% of Australian adolescents experience depression over their lifetime, with a point prevalence of ~5%. Suicide is the second leading cause of death in Australians aged 15–24, with rates rising across the 2010–2020 decade. Aboriginal and Torres Strait Islander adolescents face 2–3 times higher suicide rates; LGBTQ+ adolescents have approximately 4–5 times the suicide attempt rate of their peers.

The RANZCP 2020 Mood Disorders Clinical Practice Guideline and Orygen’s youth mental health framework provide the Australian evidence base.

A. Core clinical — the AU general-practice framework

The HEEADSSS interview

The HEEADSSS framework — Home, Education/employment, Eating, Activities, Drugs, Sexuality, Suicide/depression, Safety — is the structured psychosocial assessment tool recommended by RACGP and Orygen. See the companion article on adolescent HEEADSSS assessment for the full framework. Key principles:

State confidentiality limits up front, before any disclosure: risk-to-self, risk-to-others, and abuse override confidentiality.
Interview the young person alone for at least part of the consultation, regardless of who attended.
Ask about suicidal ideation directly — evidence confirms this does not increase risk.

Screening tools

PHQ-A (adolescent-modified PHQ-9): validated from age 11; cut-offs 5/10/15/20 for mild/moderate/moderately-severe/severe.
K10 / K5: RACGP-endorsed psychological distress screener; K5 for Aboriginal and Torres Strait Islander young people.
SDQ (Strengths and Difficulties Questionnaire): parent and self-report for younger adolescents.

Investigations

eTG and RACGP recommend bloods to exclude organic mimics and establish baseline before pharmacotherapy:

FBC (anaemia), TSH (hypothyroidism), UEC and LFTs (metabolic baseline), vitamin D (replete if low), B12 and folate, ferritin (particularly in menstruating females and vegetarians), and pregnancy test in sexually active females before initiating any SSRI (paroxetine has a cardiac defect signal in first trimester).
Urine drug screen if substance use is suspected — with explanation and consent.
EBV serology if post-viral fatigue picture.
ECG baseline if cardiac history or before any QTc-prolonging medication.

Differential diagnoses to hold in mind

Bipolar disorder (past or current mania, hypomania, mixed state, or family history — antidepressant monotherapy may precipitate a switch); anxiety disorders (extremely common comorbidity, ~50%); PTSD; substance-induced mood disorder; eating disorder; ADHD with demoralisation; emerging borderline personality disorder features (affective instability, self-harm, identity disturbance); hypothyroidism; post-viral fatigue; and medication-induced mood changes (isotretinoin, corticosteroids, some hormonal contraceptives, levetiracetam).

B. Evidence — what treatment works

Stepped care: matching intensity to severity

Per RANZCP 2020, Orygen, and headspace:

Mild depression (PHQ-A 5–9, minimal functional impairment):

Psychoeducation, safety plan, crisis lines
Lifestyle prescription: sleep hygiene, aerobic exercise (≥30 min/day has comparable effects to antidepressants in mild depression), social engagement, reduced cannabis and alcohol use, and limits on late-night screen and social media use
Self-help: ReachOut, BiteBack (Black Dog Institute), moodgym
Review in 2–4 weeks; escalate if no improvement at 4–6 weeks

Moderate depression (PHQ-A 10–14, functional impairment):

CBT or IPT-A first-line — 12–16 structured sessions. Cochrane (Cox 2014) confirms both are effective. Access via Mental Health Care Plan + psychologist referral or headspace centre.
DBT skills if self-harm or emerging borderline personality features
Continue lifestyle prescription

Severe depression (PHQ-A ≥15, severe impairment, suicidal ideation, psychotic features):

CBT plus fluoxetine combination — the TADS trial (NEJM 2007) showed 71% response at 12 weeks for combination therapy versus 61% for fluoxetine alone, 43% for CBT alone, and 35% for placebo. Combination is superior.
Psychiatric referral: headspace Youth Early Psychosis Program for emerging psychosis; state CYMHS or private adolescent psychiatry for complex severe presentations
Consider hospitalisation for imminent suicide risk, psychotic features, severe self-neglect, or unsafe home environment

Pharmacotherapy — fluoxetine is first-line

Per eTG, RANZCP 2020, and AMH:

Fluoxetine is the only SSRI with TGA approval for adolescent MDD (approved from age 8 years). Start at 10 mg, titrate to 20 mg after 1–2 weeks; therapeutic range 20–40 mg. The long half-life reduces withdrawal risk if a dose is missed — a practical advantage in adolescents.

Sertraline (second-line, off-label for adolescent MDD) and escitalopram (second-line, off-label for MDD in Australia despite FDA adolescent approval) are reasonable alternatives.

Paroxetine should be avoided in adolescents: the Study 329 re-analysis (BMJ 2015) demonstrated no efficacy benefit and an increased self-harm signal. Venlafaxine also has a suicidality signal in adolescent trials. Tricyclic antidepressants show no benefit over placebo in adolescents per Cochrane (Hazell 2013), and carry cardiotoxicity risk in overdose.

TGA Black Box Warning and monitoring requirements

All antidepressants carry a TGA Black Box Warning for under-25-year-olds regarding emergent suicidal thoughts and behaviours, predominantly in the first 2–4 weeks. The absolute increase in suicidal ideation is approximately 1–2%; there is no completed-suicide signal in trial data, and Bridge et al. (JAMA 2007) confirmed that the benefit-risk balance favours treatment for moderate-to-severe depression. Required monitoring: weekly review for the first 4 weeks, then fortnightly for the following 4 weeks. Document informed consent from the young person and (where appropriate) parent or carer explicitly in the medical record.

C. Safety planning and suicidality management

The Stanley-Brown Safety Planning Intervention

The Stanley-Brown Safety Planning Intervention (SPI) is a structured, co-produced written plan including: personal warning signs, internal coping strategies, social contacts for distraction, people to call for help, professional crisis contacts, and reasons for living. The ED-SPI RCT (JAMA Psychiatry 2018) demonstrated reduced suicidal behaviour at 6 months.

In practice: co-produce the plan with the young person using the Beyond Now app from beyondblue or a written format. Review and update it at each visit. Provide the plan to the young person and, with their consent, to their parent or carer.

Means restriction

Firearms must be removed from the household or stored with another party when a young person has active suicidal ideation. Medications — particularly paracetamol, which can cause fatal hepatotoxicity with overdose — should be stored in a locked location. RANZCP 2020 identifies means restriction as one of the highest-impact interventions for adolescent suicide prevention.

Risk assessment is dynamic, not static

Structured risk assessment identifies risk and protective factors and informs clinical decisions. It should be revisited at each consultation — risk is not fixed. Protective factors (reasons for living, family connection, future orientation, access to care, engagement with treatment) matter as much as risk factors. The formal numerical “risk level” is less important than the clinical response to the current assessment.

D. Australian operations

headspace — the core referral pathway

headspace centres (115+ Australia-wide) provide multidisciplinary, youth-friendly mental health care for ages 12–25. Services include GPs, psychologists, social workers, alcohol and other drug counsellors, and often sexual health. Most services are bulk-billed or low-cost; GP referral is helpful but not mandatory. Rural and remote young people can access telehealth via eheadspace 1800 650 890.

Mental Health Care Plan (Better Access)

MHCP preparation items (MBS 2700/2701/2715/2717) enable referral for 10 individual psychology sessions per calendar year under Better Access. Review item 2712 at the 6-session point. The plan must identify the mental health condition, evidence of assessment, and treatment goals.

Focused Psychological Strategies (FPS) can be delivered directly by GPs with FPS training (MBS 2721/2723/2725/2727) — a viable option for GPs in rural or underserved areas where psychology access is limited.

CYMHS / CAMHS referral

State Child and Youth Mental Health Services (CYMHS/CAMHS) provide tertiary assessment and management for young people with complex, severe, or treatment-refractory presentations. Criteria and access thresholds vary by state. Contact the local CYMHS intake line (state Mental Health Line) for a triage decision.

MBS items in general practice

Level B (23), C (36), and D (44) consultations; use level C or D for comprehensive HEEADSSS + structured risk assessment. ATSI Health Assessment (MBS 715/10987) includes a mental health screening component. GPCCMP (MBS 965/967) for chronic or recurrent depression with complex comorbidities. Pathology items: FBC (65070), TSH (66716), B12 (66610), folate (66611), vitamin D (66608), ferritin (66599), βhCG (66695).

PBS prescribing

Fluoxetine, sertraline, and escitalopram are on the general PBS schedule. Atypical antipsychotic augmentation (quetiapine, aripiprazole) requires Authority and specialist initiation in adolescents. Lithium requires Authority and therapeutic drug monitoring. Stimulants (methylphenidate, dexamfetamine, lisdexamfetamine) for comorbid ADHD require specialist-initiated Authority.

Mandatory reporting

Clinicians are mandatory reporters under state child-protection legislation if child abuse, neglect, or family violence is suspected. In New South Wales: Children and Young Persons (Care and Protection) Act 1998; Victoria: Children, Youth and Families Act 2005; Queensland: Child Protection Act 1999; other states and territories have equivalent legislation. The reporting obligation applies regardless of whether the young person consents.

E. Special populations

Aboriginal and Torres Strait Islander young people

Suicide rates are 2–3 times higher in Aboriginal and Torres Strait Islander adolescents than in non-Indigenous peers. Cultural safety and trauma-informed care are foundational. Engage Aboriginal Community Controlled Health Organisations (ACCHOs) and Aboriginal Health Workers where available. Use the K5 (validated ATSI short form) for psychological distress screening. Refer to social and emotional wellbeing (SEWB) services and community support workers alongside clinical treatment. The MBS 715 ATSI Health Assessment incorporates mental health screening. The crisis line 13YARN (13 92 76) provides 24/7 culturally safe support.

LGBTQ+ young people

LGBTQ+ adolescents experience approximately 4–5 times the suicide attempt rate of heterosexual, cisgender peers. Gender-affirming, LGBTQ+-inclusive care reduces minority-stress burden and improves engagement. Clinicians should ask about sexual orientation and gender identity in a normalising way as part of the HEEADSSS assessment. Refer to QLife (1800 184 527) for LGBTQ+-specific counselling and peer support. Consult headspace and Minus18 resources for young LGBTQ+ Australians.

Comorbid ADHD

ADHD and depression coexist in approximately 25% of adolescents presenting with depression. ADHD contributes to academic failure, social difficulties, and demoralisation — which can mimic or precipitate depression. Treat the conditions in parallel when both are present, in consultation with a paediatrician or child and adolescent psychiatrist for ADHD medication management.

Perinatal depression in adolescents

Adolescent mothers face compounded mental health risks. The EPDS (Edinburgh Postnatal Depression Scale) is validated for perinatal use. Referral to perinatal mental health services and additional home visiting support (via MACH nurses) reduces risk. Medication decisions require careful benefit-risk assessment given lactation and foetal considerations.

When to escalate

Emergency department (same-day):

Active suicidal plan, intent, and access to means
Recent suicide attempt (high re-attempt risk within 4 weeks)
Command auditory hallucinations
Severe self-neglect or inability to maintain safety
Psychotic features requiring urgent assessment

Same-week specialist referral (headspace or CYMHS):

Moderate-to-severe depression not responding to 4–6 weeks of first-line treatment
Suspected bipolar disorder (family history, antidepressant-induced activation, manic features)
Comorbid eating disorder with medical concerns
Substance use disorder as a prominent comorbidity
Complex trauma or emerging personality disorder features

Routine GP management continues for:

Mild depression with adequate safety plan and engaged young person
Established moderate depression with a functioning therapy relationship

Crisis lines to provide at every appointment:

Kids Helpline 1800 55 1800 (5–25y, 24/7)
Lifeline 13 11 14
eheadspace 1800 650 890
Beyond Blue 1300 22 4636
13YARN 13 92 76 (Aboriginal and Torres Strait Islander)
QLife 1800 184 527 (LGBTQ+)

What this article is and is not

This article draws on current Australian youth mental health guidelines — RANZCP 2020 Mood Disorders CPG, Orygen, headspace, RACGP mental health, eTG Psychotropic, AMH — and trial evidence including TADS (NEJM 2007) and Bridge et al. (JAMA 2007). It is not personal medical advice and does not create a doctor–patient relationship. Assessment of a young person with possible depression requires individual clinical judgment, direct consultation, and — where suicidality is present — careful safety planning with the young person and their family.

For immediate help: Kids Helpline 1800 55 1800, Lifeline 13 11 14, Beyond Blue 1300 22 4636. For crisis: call triple zero (000) or go directly to your nearest emergency department.

Sources cited

Frequently asked questions

How is depression in adolescents different from normal teenage moodiness?

Normal adolescent development involves moodiness, identity exploration, and heightened emotion — this is expected and does not meet criteria for depression. Pathological depression requires at least five DSM-5 symptoms (including depressed or irritable mood, or loss of interest) persisting most of the day, most days, for at least two weeks, with real impairment in school, social, or home functioning. Irritability — not just sadness — is a common dominant feature in adolescents with depression. Other clues: withdrawal from friends and activities, school refusal, significant changes in sleep or appetite, and expressions of hopelessness or worthlessness that are disproportionate to circumstances.
Is it safe to use antidepressants in young people?

Antidepressants — including fluoxetine — are used for moderate to severe adolescent depression when therapy alone is insufficient. The TGA (and FDA) require a Black Box Warning for all antidepressants in under-25-year-olds: there is a small increase (about 1–2%) in suicidal thoughts and behaviours in the first 2–4 weeks of treatment. Weekly review during this period is required. Crucially, untreated moderate-to-severe depression carries a higher overall suicide risk than treated depression — the benefit-risk analysis still supports treatment when indicated. The decision is made carefully, with fully informed consent from the young person and their family.
What is headspace and how does my young person get there?

headspace is Australia's national youth mental health organisation, operating 115+ centres that provide multidisciplinary mental health care for people aged 12–25. Services include GPs, psychologists, social workers, and alcohol and other drug workers. Many services are bulk-billed or low-cost. A GP referral is helpful but not required for an initial headspace appointment. Walk-in is accepted at many centres. eheadspace (1800 650 890) provides telehealth support for those who cannot access a local centre, including rural and remote young people. headspace is the most accessible entry point for mild-to-moderate youth mental health concerns across Australia.
What should I do if a young person mentions thoughts of suicide?

Ask directly and calmly — research confirms that asking about suicide does not increase risk. Assess the level of risk: has the young person thought about how they might do it, made any preparations, or made a previous attempt? A safety plan — ideally co-produced using the Stanley-Brown approach — identifies warning signs, coping strategies, people to contact, and reasons for living. Ensure means restriction: medications should be stored locked, firearms removed, and paracetamol limited in the household. Active suicidal plan with intent and access to means requires same-day emergency assessment. The Beyond Now app (beyondblue) supports digital safety planning.
What therapy works best for adolescent depression?

Cognitive behavioural therapy (CBT) and interpersonal therapy for adolescents (IPT-A) are both first-line psychological treatments for moderate adolescent depression with strong evidence. For severe depression, the TADS trial (published in NEJM 2007) showed that combining CBT with fluoxetine produced a 71% response rate — significantly better than either treatment alone. In Australia, therapy is accessed via a Mental Health Care Plan and referral to a psychologist through the Better Access program (up to 10 sessions per year) or through headspace centres, which often have integrated psychological services.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.